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BACKGROUND: High-risk human papillomavirus (H-HPV) infection is linked to cervical neoplasia but its role in detecting cervical
glandular lesions (GLs) is unclear. Carbonic anhydrase IX (CA-IX) is a hypoxic biomarker that is highly expressed in neoplastic cervical
GLs. The diagnostic utility of these biomarkers was evaluated by the Gynecologic Oncology Group in Japanese women with
a cytological diagnosis of atypical glandular cells.
METHODS: Immunostaining was used to detect CA-IX in a conventional Pap smear. Immunoreactivity of CA-IX was interpreted by a
panel of pathologists blinded to the histological diagnosis. Polymerase chain reaction was used to detect H-HPV in a liquid-based
cytology specimen.
RESULTS: Significant cervical lesions (SCLs), defined as cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ or invasive
carcinoma, were observed in 37/88 (42%) of women. CA-IX testing alone (n¼ 88) had a sensitivity of 89, 100 or 73% for SCLs, GLs
or significant squamous lesions (SLs), respectively, with a false negative rate (FNR) of 14%. Testing for H-HPV (n¼ 84) had a
sensitivity of 65, 53 or 80% for SCLs, GLs or SLs, respectively, with a FNR of 22%. The combination of CA-IX and H-HPV testing had
a sensitivity of 97, 100 or 93% for SCLs, GLs or SLs, respectively, with a FNR of 5%. Among eight H-HPV-negative GLs, six (75%) had
a diagnosis of lobular endocervical glandular hyperplasia (LEGH).
CONCLUSION: The combination of CA-IX and HPV testing improved the diagnostic accuracy. The low rate of H-HPV positivity in the
GLs was associated with coexisting LEGH independent of H-HPV.
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Cervical cancer is the second most common cause of cancer death
in women worldwide, with an estimated 510 000 newly diagnosed
cervical cancer cases and 288 000 deaths annually (Pagliusi, 2006).
Although implementation of nationwide cervical cytological
screening programs has led to a dramatic decline in the incidence
of cervical squamous cell carcinoma, the rate of endocervical
adenocarcinomas is on the rise, particularly in young women
(Smith et al, 2000; Bray et al, 2005). The false negative rate in the
cytological test for cervical adenocarcinomas, generally speaking,
is higher than that for squamous lesions (SLs) (Makino et al, 1995).
Several factors may contribute to such a difference; ill-defined
cytological criteria for separating neoplastic glandular cells from
benign mimics may have an important role.
In 2001, the Bethesda System introduced the term ‘atypical
glandular cells (AGCs)’, replacing the term ‘AGCs of undetermined
significance’, thereby classifying glandular cell abnormalities
exceeding those typical reactive changes, but lacking features
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diagnostic of adenocarcinoma, into the following three categories:
AGC of unclear cell origin, atypical endocervical cells and atypical
endometrial cells (Solomon et al, 2002). However, in clinical
practice, such a sub-categorization of AGC remains a diagnostic
challenge with poor inter-observer agreement. The studies show
that 17–80% (mean, 41%) of women with an AGC diagnosis
were found to harbour significant cervical lesions (SCLs),
including high-grade cervical intraepithelial neoplasia (CIN2 and
CIN3), adenocarcinoma in situ (AIS) and invasive carcinoma.
The rate of invasive carcinoma has been reported to be up to 10%
(Liao and Stanbridge, 2000; Lee et al, 2002; Cangiarella and
Chhieng, 2003).
From the clinical point of view, young women with AGC are
often treated aggressively with cervical conization because of the
relative lack of accuracy of colposcopy and endocervical curettage
for excluding SCLs. It has been well documented that SCLs,
including invasive carcinoma, may exist in AGC patients even
when the results of colposcopic examination and endocervical
sampling are normal (Andersen and Arffmann, 1989). Therefore,
from a cost-benefit standpoint, and from a desire to avoid
unnecessary invasive procedures, an accurate screening method
or test is needed to determine which women with a cytological
diagnosis of AGC harbour a SCL. In the recent years, many
biomarkers have been developed and, among those, human
papillomavirus (HPV) and carbonic anhydrase IX (CA-IX) appear
to be particularly promising.
Infection with oncogenic high-risk HPV (H-HPV) strain(s) is
widely accepted to be an important aetiologic factor for cervical
cancer (zur Hausen, 2002; Schiffman et al, 2007; Bosch et al, 2008).
Clinical trials have established the importance of H-HPV testing
for the detection of significant SLs, including CIN2, CIN3 and
squamous cell carcinoma (Solomon et al, 2001). Furthermore,
H-HPV has been detected in 80– 90% of adenocarcinomas and
their precursor glandular lesions (GL) (Pirog et al, 2000; Bosch
et al, 2008). However, there are only limited data available with
respect to H-HPV testing as a diagnostic tool in the detection of
glandular neoplasia.
In the 1990s, the antigen MN was identified (Zavada et al, 1993).
The antigen MN is a transmembrane glycoprotein, and is a
member of the carbonic anhydrase gene family, and is more
specifically designated carbonic anhydrase IX (CA-IX) (Opavsky
et al, 1996). The CA-IX is a biomarker of several human tumours,
including carcinomas of the cervix and kidney (Liao et al, 1994,
1997). The expression of CA-IX in cancerous tissues, and its
absence in normal counterparts, has led to the speculation that it
has a function in carcinogenesis (Wykoff et al, 2000; Ivanov et al,
2001). Its expression is controlled by the transcription factor,
hypoxia-inducible factor-1, and is upregulated in hypoxic regions
of tumour tissues (Swietach et al, 2007).
In a survey of benign and neoplastic cervical tissues and Pap
smears (PSs), it was observed that virtually all AGC associated with
AIS and adenocarcinoma expressed high levels of CA-IX antigen,
but this biomarker was rarely detected in the benign cervical cells/
cervical tissues. This suggested the possibility that the expression
of CA-IX may serve as a useful biomarker for diagnosing AIS and
adenocarcinoma (Liao et al, 1994, 2009; Liao and Stanbridge, 1996,
2000).
In 1998, the Gynecologic Oncology Group (GOG), a national
multi-institutional clinical trials group, supported by the US
National Cancer Institute, conducted a study of women with a
cytological diagnosis of AGC. In total, 25 institutions in the United
States and 11 institutions in Japan participated in the trial. Here,
we report the results from the Japanese cohort. The objective of
this study, included in GOG protocol #171, was to determine
whether CA-IX expression in a conventional PS is a diagnostic
biomarker for a SCL in Japanese women with a cytological
diagnosis of AGC and to explore the diagnostic value of H-HPV
testing alone or in combination with CA-IX.
MATERIALS AND METHODS
GOG protocol #171 initiated accrual in the United States in
1998 and in Japan in 2003. The criteria of AGC diagnosis for
patient enrollment were based on the 1991 Bethesda System
classification and conventional PSs were used. PCR was used
to detect H-HPV DNA in corresponding liquid-based cytology
specimens. The protocol closed for accrual in both countries
in 2005.
Eligibility and clinical management
Women over the age of 18 years, with a referring diagnosis of AGC,
who were expected, on a clinical basis, to undergo complete
histological evaluation of the cervical transformation zone within
6 months of the initial cytological diagnosis were enrolled. Patients
with a history of endometrial hyperplasia and/or carcinoma of the
uterine corpus, cervix and vagina; previous or concurrent chemo-
therapy and/or radiation to the uterine corpus, cervix and vagina;
or HIV infection were excluded. All patients received colposcopic
examination, cervical biopsy, endocervical curettage and/or
an endometrial biopsy as clinically indicated, as well as either
loop electrosurgical excision cone biopsy of the cervix with an
endocervical curettage, a cold knife cone biopsy of the cervix
with/without an endocervical curettage or a hysterectomy within
6 months of the initial cytological diagnosis of AGC. An endo-
metrial biopsy or curettage was obtained in all premenopausal and
postmenopausal women, as well as in all patients with a negative
cone biopsy of the cervix. Patients with a negative diagnosis after
the cervical cone biopsy, but not undergoing a hysterectomy, were
to be followed with routine PS screening every 6 months for
2 years. Informed consent consistent with federal, state and local
requirements was obtained before enrollment. Before activation,
the protocol was approved by the National Cancer Institute,
Division of Cancer Prevention and the GOG Human Research
Committee, and annually by the Institutional Review Board at each
of the participating institutions.
Sample collection
After enrollment, two cytology specimens were collected before
surgical procedures were performed. At first, a spray-fixed conven-
tional study PS was taken with a spatula and cytobrush and stained
according to the Pap method. A second sample was obtained
with a sampling device and suspended in 20 ml of the PreservCyt
Solution (Cytyc/Hologic, Marlborough, MA, USA) for H-HPV
DNA testing.
Histological samples were taken by punch biopsy, endocervical
and/or endometrial curettage or loop electrosurgical excision or
cold knife cone excision at colposcopy and/or hysterectomy,
as clinically indicated. Specimens were fixed in 10% formalin,
paraffin embedded, sectioned and stained with hematoxylin and
eosin.
Histological diagnosis
Hematoxylin and eosin-stained slides of the most abnormal lesions
from each diagnostic procedure were reviewed centrally by teams
of two pathologists from the GOG Pathology Committee who
reached a consensus diagnosis. Disparities were arbitrated by a
third GOG pathologist. A positive diagnosis, coded as a SCL,
reflects the presence of CIN2, CIN3, AIS or invasive carcinoma in
the cervix. A negative diagnosis represents the absence of SCLs,
including CIN1 and atypia. Atypia was defined as glandular and
SLs in which cellular atypia falls short of AIS and CIN1. Evaluation
of the entire cervical transformation zone was required to make
a negative diagnosis, but not to make a positive diagnosis. The
significant lesions were restricted to the cervix and there was
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no case of vaginal dysplasia/neoplasia without the coexisting
cervical lesions or lesions outside the uterus identified in the study.
Retrospective evaluation of the histology in all cases with the
knowledge of the H-HPV and CA-IX status was conducted by
one pathologist (SYL). The hematoxylin and eosin-stained
sections of all GLs, and those cases that were negative for
H-HPV DNA, but expressed CA-IX, were also independently
reviewed by a second pathologist (WHR) who was blinded to the
clinical data.
Detection of CA-IX in a conventional study PS
CA-IX testing was performed in conventional study PS using the
anti-CA-IX mouse monoclonal antibody, M75, as described
previously (Liao et al, 1994; Liao and Stanbridge, 1996, 2000).
Specific immunostaining was defined by the presence of a brown
reaction product on the plasma membrane under  40 magnifica-
tion. Faint staining of the cytoplasm was considered negative.
Cytological criteria for atypical cells, delineated in the Bethesda
System classification, were used in the diagnostic classification
(Kurman and Solomon, 1994). Immunostaining was scored as
positive (pattern A and B) or negative (pattern C and D) based on
the staining intensity (strong vs weak/negative) and immuno-
reactive patterns (diffuse vs focal). Strong positivity represented
dark brown immunoreactivity that was easily identified at a low-
power magnification ( 4 or  10). The diffuse staining pattern
was defined as more than 50% of the cytologically atypical or
normal endocervical cells in the smear showed immunoreactivity
to CA-IX. The patterns A, B, C and D were defined as follows:
(A) when individual atypical cells and/or cell clusters showed
Pattern A Atypical cells
Pattern B Normal cells
Pattern C Weak staining
Pattern D Non-staining
LEGH Atypia Adeno Ca.
Figure 1 The four scoring patterns of CA-IX immunoreactivity in PSs containing AGC and representative illustrations of the cases with LEGH. Patterns
A and B: positive immunostaining in the atypical cells/cell clusters (A) or in the normal looking endocervical cells (B). Patterns C and D: weak positive (C)
or no immunoreactivity (D) in normal cervical cells. The original low power magnification ( 100) of patterns A, B, C and D shown in the left panels and
the corresponding cell clusters marked with arrow shown in the left panel ( 400). The case of LEGH exhibits lobular proliferation of the small glands
surrounding the larger gland (original magnification  100) with focal nuclear atypia (single arrow: benign glands, double arrow: atypia) and the area of
well-differentiated adenocarcinoma (original magnification,  400).
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specific immunoreactivity that was either diffuse or focal; (B) when
normal-looking endocervical cells exhibited focal or diffuse strong
specific positive staining; (C) when the normal endocervical cells
showed focal, but weak staining and; (D) when there was non-
specific faint cytoplasmic positivity or lack of staining observed at
 40 magnification (Figure 1). A set of teaching smears with
samples of known negative and positive CA-IX immunoreactivity
was provided by one of the authors (SYL). After the training
session, the CA-IX immunostained smears were evaluated and the
interpretation in each case was recorded independently by 3 cyto/
gynecologic pathologists (SYL, WHR and TAB) blinded to
histological diagnosis. Any cases with different classification of
immunostaining patterns were reviewed simultaneously by three
study pathologists, using a multi-headed microscope. A consensus
was obtained when at least two of the three study pathologists
reached agreement. The results of the consensus were entered to
the GOG Statistical database as the final score for each patient in
the study.
HPV genotyping
The detection method employed a modified E6/E7-specific
consensus PCR, using mixed primers (pU-1M, pU-1M-L/pU-2R
and pU-2R-N). The PCR method used was a minor modification of
published procedures (Inoue et al, 1995; Yamazaki et al, 2001) in
which modification of the primer sequences made it possible to
amplify 13 H-HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 58,
67, 68 and 70). The PCR-based procedure was performed on 84 of
88 specimens by the Takara Bio Corporation (Otsu, Shiga, Japan).
The sequence of the PCR reactions was 941C for 30 s, 551C for 60 s
and 721C for 60 s, and each cycle was repeated 35 times. PCR
product size ranged from 231 to 271 base-pairs and represent the
E6 and E7 regions of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 67, 68
or 70. Genotyping of H-HPV DNA was performed according to the
restriction fragment length polymorphism method described by
Lungu et al (1992). In situations where genotyping was not
detected by restriction enzyme analysis, genotyping was deter-
mined by direct sequencing of the amplified products.
Statistical methods
Statistical analyses were performed using Statistical Analysis
System version 9.1 (SAS Institute Inc., Cary, NC, USA). Sensitivity,
specificity, positive predictive value and negative predictive value,
interpreted as the risk of a SCL among women who test negative
for H-HPV and/or CA-IX, and overall accuracy were calculated
using the definition of FNR as 1 minus negative predictive value
for women diagnosed by CA-IX or H-HPV status, individually
or jointly, relative to histological diagnosis. When used in
combination, the following decision rule was employed: if either
CA-IX or HPV was positive, then the case was said to be test
positive.
RESULTS
A total of 92 Japanese women with a cytological diagnosis of AGC
were enrolled in the study. Four women were excluded because of
the unsatisfactory study PS (n¼ 3) and incomplete histological
evaluation of the cervix (n¼ 1). The age distribution of the patients
ranged from 29 to 80, with a median age of 46. Details are given in
Table 1. All patients were of Asian origin. Of the 88 eligible patients
enrolled in the study, 37 (42%) women had a SCL. Among those
with a SCL (n¼ 37), 15 (41%) harboured a significant SL, including
CIN2 (n¼ 3), CIN3 (n¼ 11) and squamous cell carcinoma (n¼ 1),
and 22 (59%) had a significant GL, comprising AIS (n¼ 14),
Table 1 Clinical characteristics and histology diagnosis
Clinical characteristics
Patient age
n¼ 88 (%)a
n¼ 84 (%)b
HPV (PCR)
Age All cases HPV (+) HPV ()
p30 1 (1) 1 (1) 0
31–40 22 (25) 10 (12) 10 (12)
41–50 31 (35) 11 (13) 18 (23)
51–60 24 (27) 7 (8) 17 (20)
61–70 6 (7) 0 5 (6)
X71 4 (5) 0 4 (5)
Histological diagnosis n¼ 88 (%)a
Insignificant cervical lesions 51 (58) Significant cervical lesions 37 (42)
Negative/benign 34 Squamous lesions 15 (41) Glandular Lesions 22 (59)
Negative, NOSa 24 CIN2 3 Adenocarcinoma in situ 14
Metaplasia, NOS 3 CIN3 11 Invasive adenocarcinoma 8
Squamous metaplasia 7 Squamous cell carcinoma 1 Adenocarcinoma NOS 7
Atypiac 6 Adenosquamous 1
Glandular hyperplasia 5
CIN1: mild dysplasia 6
Abbreviations: AIS¼ adenocarcinoma in situ; CA-IX¼ carbonic anhydrase IX; CIN¼ cervical intraepithelial neoplasia; HPV¼ human papillomavirus; NOS¼ not otherwise
specified. CIN2, moderate dysplasia; CIN3, severe dysplasia/in situ squamous carcinoma. aA total of 88 cases were tested for CA-IX expression. bAmong 88 cases, 84 were also
tested for high-risk HPV. cIncluding glandular and squamous lesions in which cellular atypia falls short of AIS and CIN1.
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invasive adenocarcinoma (n¼ 7) and adenosquamous carcinoma
(n¼ 1). Details are presented in Table 1.
Accuracy of CA-IX testing
Of the 88 women enrolled in the study, 60 (68%) cases showed
positive staining for the CA-IX in the conventional study PS.
Among these positive cases, 33 (55%) had a SCL, including 11 SLs
and 22 GLs. Thus, CA-IX immunoreactivity identified 33 of 37
(89%) SCLs with sensitivities of 73% for SLs and 100% for GLs.
The overall specificity was 47%, with a FNR, defined as one minus
the negative predictive value, equal to 14%, which indicates that
14% of the negative diagnoses were incorrect. Details are presented
in Tables 2 and 3.
Accuracy of H-HPV testing
The PCR-based H-HPV genotyping could only be performed in 84
of the eligible Japanese women with a liquid-cervical cell sample.
H-HPV DNA was detected in 29 (35%) cases. Patient ages ranged
from 29 to 71, with a median age of 43 for the H-HPV positive
group and 49 for the H-HPV negative group (Table 1). Among the
29 H-HPV-positive cases, 22 (76%) had a SCL, including 12 SLs
and 10 GLs. Thus, H-HPV testing identified 65% (22 out of 34)
SCLs with sensitivities of 80% (12 out of 15) for SLs and 53%
(10/19) for GLs. The overall specificity was 86%, with a FNR of
22% (Tables 2 and 3). The individual H-HPV genotyping results
are given in Table 4. In the negative category, including glandular
hyperplasia, atypia and CIN1, 7 of 50 (14%) specimens were
positive. Each specimen had only one H-HPV type: three were
type 52 and one each contained types 18, 33, 45 or 51. In the SL
category, 12 of 15 (80%) specimens were positive. All of these
positive specimens contained a single genotype: two were type 16;
four were type 18; one was type 31; three were type 52; and one was
type 58. The single squamous cell carcinoma specimen contained
H-HPV types 16 and 33. Thus, the vast majority of SLs contained
a single H-HPV genotype, with types 16, 18 and 52 being the
most common. In the GLs, 10 of 19 (53%) were H-HPV positive.
Of these 10 positive cases, two were type 16, seven were type
18 and 1 contained types 16 and 18. Details are presented in
Tables 2 and 4.
The combined accuracy of CA-IX and H-HPV testing
Combined CA-IX and H-HPV testing detected the additional
11 H-HPV-negative cases (two CIN3 and nine GLs). Thus, the
overall sensitivity for SCLs, GLs or SLs was 97, 100 or 93%,
respectively, with a specificity of 42%, and a FNR of 5% (Table 3).
Retrospective histological evaluation
Retrospective histological evaluation was conducted on all cases by
one of the authors (SYL). The diagnosis was confirmed in all cases
but two. Those two cases were entered in the GOG database as
CIN3 and adenosquamous carcinoma, respectively, but no SCLs
could be identified retrospectively. Surprisingly, when the criteria
proposed by Nucci et al for lobular endocervical glandular
hyperplasia (LEGH) (Nucci et al, 1999) were applied to the
pathological diagnoses, 13 cases with histological features of
LEGHs were identified (Figure 1). All of these cases were
independently reconfirmed by the second pathologist (WHR)
blinded to the H-HPV and CA-IX data. The age distribution of
cases with LEGH ranged from 36 to 80 with the mean of 54. Those
cases with LEGHs were diagnosed as benign cervix (n¼ 3),
glandular hyperplasia (n¼ 2), atypia (n¼ 1), CIN2 (n¼ 1) and
GLs (n¼ 6) by the panel of pathologists at the GOG central review.
Six of 13 cases (43%) with LEGHs had coexistent in-situ (n¼ 3)
and/or extremely well-differentiated invasive adenocarcinoma,
also termed ‘minimal deviation adenocarcinoma’ (n¼ 3). All 13
LEGHs were HPV negative, but showed positive CA-IX expression
in the PS. None of H-HPV-positive GLs had a coexistent
LEGH histology. The results of retrospective histological evaluation
and the corresponding H-HPV and CA-IX data are shown in
Table 5.
Table 2 Biomarker test (CA-IX, HPV and CA-IX+HPV) results by
histological diagnosis
Histological diagnosis
Biomarker
test
Insignificant
cervical lesions SLs GLs
All SCLs
(SLsþGLs)
Total numbera 88 (%) 51 (58) 15 (17) 22 (25) 37 (42)
CA-IX
Negative 28 (32) 24 (47) 4 (27) 0 4 (11)
Positive 60 (68) 27 (53)b 11 (73) 22 (100) 33 (89)
Total numberc 84 (%) 50 (59) 15 (18) 19 (23) 34 (40)
CA-IX
Negative 47 (56) 43 (86) 4 (27) 0 4 (12)
Positive 37 (44) 7 (14) 11 (73) 19 (100) 30 (88)
HPV (PCR)
Negative 55 (55) 43 (51) 3 (20) 9 (47) 12 (35)
Positive 29 (35) 7 (14)b 12 (80) 10 (53) 22 (65)
CA-IX+HPV
Negative 22 (26) 21 (42) 1 (7) 0 1 (3)
Positive 62 (74) 29 (58) 14 (93) 19 (100) 33 (97)
Abbreviations: AIS¼ adenocarcinoma in situ; CA-IX¼ carbonic anhydrase IX;
CIN¼ cervical intraepithelial neoplasia; GL¼ glandular lesion; HPV¼ human papillo-
mavirus; SCL¼ significant cervical lesion; SL¼ squamous lesion. Insignificant cervical
lesions, including negative/benign, CIN1, atypia and glandular hyperplasia; SLs: CIN2,
CIN3 and squamous cell carcinoma; GLs: AIS and adenocarcinoma. aAll cases tested
for CA-IX. bIncluding two CIN1, one atypia and one hyperplasia. cCases in which HPV
(HC2) results were available.
Table 3 Diagnostic accuracy of CA-IX, HPV and CA-IX+HPV
Sensitivity
Numbers tested Biomarkers SCLs SLs GLs Specificity NPV PPV FNRa
88 CA-IX 0.89 0.73 1.00 0.47 0.86 0.55 0.14
84 CA-IX 0.88 0.73 1.00 0.50 0.86 0.54 0.14
HPV (PCR) 0.65 0.80 0.53 0.86 0.78 0.76 0.22
HPV (PCR)+CA-IX 0.97 0.93 1.00 0.42 0.95 0.53 0.05
Abbreviations: CA-IX¼ carbonic anhydrase IX; FNR¼ false negative rate; GL¼ glandular lesion; HPV¼ human papillomavirus; NPV¼ negative predictive value; PPV¼ positive
predictive value; SCL¼ significant cervical lesion; SL¼ squamous lesion aFNR: defined as 1 NPV to reflect the proportion of negative diagnosis that was incorrect.
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DISCUSSION
In agreement with previous studies, a wide spectrum of benign and
clinically significant lesions was identified in follow-up evaluation
of patients with a diagnosis of AGC enrolled in the Japanese cohort
of GOG protocol #171. The rate of significant uterine lesions in
published studies of AGC has ranged from 17 to 80% (mean, 41%),
with ranges of 0– 34% (mean, 11%) for women with GLs, 5– 43%
(mean, 17%) for those with SLs and 0–23% (mean, 9%) for those
with invasive carcinomas, with most of the latter being
of endocervical or endometrial origin (Veljovich et al, 1998;
Cangiarella and Chhieng, 2003). In this study we report that 42%
(37/88) of women had a SCL, including 15 with a SL and 22 with a
GL. The overall rate of invasive carcinoma was 10%. Among the 37
SCLs, 59% were GLs and 24% were invasive cervical carcinoma.
The results are within the ranges formerly published.
H-HPV DNA detection has been strongly linked with SCLs;
however, published data on the utility of H-HPV testing in AGC
diagnosis is limited. Our recent data suggested that, in the United
States, H-HPV testing is a useful biomarker for identifying SCLs in
women with a cytological diagnosis of AGC, and has an overall
sensitivity of 97, 100 or 96% for SCLs, GLs or SLs, respectively, and
a FNR of 1% (Liao et al, 2009). The current study, however,
revealed a low detection rate for H-HPV in SCLs with overall
sensitivities of 65, 53 or 80% for SCLs, GLs or SLs, respectively, and
a FNR of 22% in this cohort of Japanese women. Retrospective
review of the histology of all H-HPV-negative GLs (n¼ 8)
identified six cases that were associated with LEGH. The diagnosis
of LEGH in each specimen was confirmed by positive immuno-
staining of the lesion with an anti-MUC-6 antibody (Mikami et al,
2004, and data not shown). LEGH is a rare lesion of the uterine
cervix; it usually occurs in postmenopausal women and has been
proposed that LEGH represents pre-cancerous minimal deviation
adenocarcinoma (extremely well-differentiated adenocarcinoma),
independent of H-HPV infection.
None of the reported cases of LEGH contained H-HPV (Xu et al,
2005; Nara et al, 2007; Kawauchi et al, 2008). There were two cases
of AIS without associated LEGH that were negative for H-HPV. In
one AIS case the lesion was very focal and limited and the other
AIS case stained negatively for p16, a biomarker strongly
correlated with H-HPV expression (Negri et al, 2003). In contrast,
high levels of p16 expression were seen in all H-HPV-positive SCLs
(data not shown). Although one cannot exclude the possibility of a
rare H-HPV type that was not represented in the testing kit, the
findings appear to suggest that in this Japanese population, SCLs
may not be solely due to H-HPV infection. Thus, H-HPV testing
alone probably will not be able to identify all SCLs, especially in
postmenopausal Japanese women. As mentioned in the results,
there were two cases that were included in SCLs category for the
data analysis; however, retrospective review of these two cases
showed that there were no SCLs present in the tissue sections.
These two cases were H-HPV negative. In order to avoid any bias
issue the data presented in the paper were based on the results
rendered by the central pathology review, which was blinded to the
knowledge of histological diagnosis. However, if these two cases
were reclassified as negative cases, there is a slightly increased
sensitivity of H-HPV testing (69, 86 or 56% for SCLs, GLs or SLs,
respectively).
Our current study confirms the diagnostic utility of CA-IX in
detecting glandular neoplasia of the cervix (Liao et al, 1994; Liao
and Stanbridge, 1996, 2000). Practically, all exfoliative endocervical
glandular cells derived from the neoplastic glands in all cases of
AIS and adenocarcinoma showed diffuse and strong CA-IX
Table 4 Distribution of HPV types in individual HPV-positive cases
HPV genotypes
Histological diagnosis
Number of
HPV-positive cases 16 18 31 33 35 39 45 51 52 58 67 70
Negative/benign 4 1 1 2
Glandular hyperplasia 0
Atypia 0
CIN1 (mild dysplasia) 3 1 1 1
CIN2 2 1 1
CIN3 9 2 3 3 1
Squamous cell carcinomaa 1 1 1
Adenocarcinoma in situb 6 3 4
Adenocarcinoma, NOS 4 4
Total HPV-positive cases 29 6 13 1 2 1 1 6 1
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HPV¼ human papillomavirus; NOS¼ not otherwise specified. CIN2: moderate dysplasia; CIN3: severe dysplasia/in situ
squamous carcinoma. Note: one squamous cell carcinoma. aContained HPV 16 and 31 and one adenocarcinoma in situ. bContained HPV 16 and 18; all other positive cases
contained a single HPV type.
Table 5 Retrospective histological evaluation with the correlation of
HPV status and CA-IX expression in the Pap smears
Histology
Case no.
(N¼84)
HPV no. of
positive
cases (%)
CA-IX expression
no. of positive
cases (%)
Negative/benign 32 4 (13) 12 (39)
Glandular hyperplasia NOS 3 0 (0) 0 (0)
Atypia 5 0 (0) 2 (40)
CIN1 6 3 (50) 5 (83)
SCLs without LEGH
CIN 2, CIN 3 12 11(92) 10 (83)
AIS 8 6 (75)a 8 (100)
Adenocarcinoma 4 4 (100) 4 (100)
Squamous cell carcinoma 1 1 (100) 1 (100)
LEGH 6 0 (0) 6 (100)
LEGH with SCLs
CIN 2 1 0 (0) 1 (100)
AIS 3 0 (0) 3 (100)
Adenocarcinoma 3 0 (0) 3 (100)
Abbreviations: AIS¼ adenocarcinoma in situ; CA-IX¼ carbonic anhydrase IX;
CIN¼ cervical intraepithelial neoplasia; HPV¼ human papillomavirus; LEGH¼ lobu-
lar endocervical glandular hyperplasia; NOS¼ not otherwise specified; SCLs¼ signi-
ficant cervical lesions. aTwo HPV-negative cases, in one case was also p16 negative
and in the other the lesion was limited.
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immunoreactivity. These CA-IX-positive cells are easily identified
at  4– 10 magnification. The patterns of CA-IX expression are
identical to those previously reported (Liao et al, 1994; Liao and
Stanbridge, 2000; Liao et al, 2009). The high levels of CA-IX
expression in LEGHs without associated GLs seen in the study is
an intriguing finding; however, it has been proposed that LEGH
may be a precursor of minimal deviation adenocarcinoma thus,
further investigation is warranted.
Despite the relatively low detection rate of CA-IX for SLs, and
H-HPV for GLs, the combined CA-IX/H-HPV testing had a
sensitivity of 97, 93 and 100% for SCLs, SLs and GLs, with a FNR of
0.05%. If the results of retrospective review were used for data
analysis then the combined CA-IX/H-HPV testing had a sensitivity
of 100% for SCLs with 0% FNR. Thus, the study concludes that the
combination of CA-IX with H-HPV testing significantly improved
the diagnostic accuracy in Japanese women with AGC diagnosis;
the low rate of H-HPV positivity in the GLs was probably
attributed to coexisting LEGH independent of H-HPV; CA-IX
testing identified all cases of GLs associated with LEGH; and lastly,
most H-HPV-positive specimens contained a single genotype. The
replacement protocol, GOG #237, opened to accrual in February
2009 to prospectively test the conclusions reported herein.
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